Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

The PAX-SIX-EYA-DACH network modulates GATA-FOG function in fly hematopoiesis and human erythropoiesis.

Creed TM, Baldeosingh R, Eberly CL, Schlee CS, Kim M, Cutler JA, Pandey A, Civin CI, Fossett NG, Kingsbury TJ.

Development. 2020 Jan 3;147(1). pii: dev177022. doi: 10.1242/dev.177022.

PMID:
31806659
2.

MicroRNAs as regulators and effectors of hematopoietic transcription factors.

Kim M, Civin CI, Kingsbury TJ.

Wiley Interdiscip Rev RNA. 2019 Sep;10(5):e1537. doi: 10.1002/wrna.1537. Epub 2019 Apr 21. Review.

PMID:
31007002
3.

Preface.

Civin CI, Kingsbury TJ, Kim M, Fisher PB.

Adv Cancer Res. 2019;141:xi-xiii. doi: 10.1016/S0065-230X(19)30008-9. No abstract available.

PMID:
30691687
4.

Regulation of cancer stem cell properties by SIX1, a member of the PAX-SIX-EYA-DACH network.

Kingsbury TJ, Kim M, Civin CI.

Adv Cancer Res. 2019;141:1-42. doi: 10.1016/bs.acr.2018.12.001. Epub 2019 Jan 16.

PMID:
30691681
5.

A Fluidic Culture Platform for Spatially Patterned Cell Growth, Differentiation, and Cocultures.

Lembong J, Lerman MJ, Kingsbury TJ, Civin CI, Fisher JP.

Tissue Eng Part A. 2018 Dec;24(23-24):1715-1732. doi: 10.1089/ten.TEA.2018.0020. Epub 2018 Jul 13.

6.

STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.

Simpson HM, Furusawa A, Sadashivaiah K, Civin CI, Banerjee A.

Oncotarget. 2018 Mar 30;9(24):16792-16806. doi: 10.18632/oncotarget.24698. eCollection 2018 Mar 30.

7.

Deterministic Lateral Displacement: The Next-Generation CAR T-Cell Processing?

Campos-González R, Skelley AM, Gandhi K, Inglis DW, Sturm JC, Civin CI, Ward T.

SLAS Technol. 2018 Aug;23(4):338-351. doi: 10.1177/2472630317751214. Epub 2018 Jan 23.

PMID:
29361868
8.

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T.

J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8.

9.

Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia.

Sasaki T, Rivera-Mulia JC, Vera D, Zimmerman J, Das S, Padget M, Nakamichi N, Chang BH, Tyner J, Druker BJ, Weng AP, Civin CI, Eaves CJ, Gilbert DM.

Exp Hematol. 2017 Jul;51:71-82.e3. doi: 10.1016/j.exphem.2017.04.004. Epub 2017 Apr 19.

10.

Automated leukocyte processing by microfluidic deterministic lateral displacement.

Civin CI, Ward T, Skelley AM, Gandhi K, Peilun Lee Z, Dosier CR, D'Silva JL, Chen Y, Kim M, Moynihan J, Chen X, Aurich L, Gulnik S, Brittain GC, Recktenwald DJ, Austin RH, Sturm JC.

Cytometry A. 2016 Dec;89(12):1073-1083. doi: 10.1002/cyto.a.23019. Epub 2016 Nov 22.

11.

Uncovering low-dimensional, miR-based signatures of acute myeloid and lymphoblastic leukemias with a machine-learning-driven network approach.

Candia J, Cherukuri S, Guo Y, Doshi KA, Banavar JR, Civin CI, Losert W.

Converg Sci Phys Oncol. 2015 Dec;1(2). pii: 025002. Epub 2015 Dec 21.

12.

MIM regulates the trafficking of bone marrow cells via modulating surface expression of CXCR4.

Zhan T, Cao C, Li L, Gu N, Civin CI, Zhan X.

Leukemia. 2016 Jun;30(6):1327-34. doi: 10.1038/leu.2016.39. Epub 2016 Feb 29.

13.

Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs.

Fox JM, Moynihan JR, Mott BT, Mazzone JR, Anders NM, Brown PA, Rudek MA, Liu JO, Arav-Boger R, Posner GH, Civin CI, Chen X.

Oncotarget. 2016 Feb 9;7(6):7268-79. doi: 10.18632/oncotarget.6896.

14.

Inefficient megakaryopoiesis in mouse hematopoietic stem-progenitor cells lacking T-bet.

Furusawa A, Sadashivaiah K, Singh ZN, Civin CI, Banerjee A.

Exp Hematol. 2016 Mar;44(3):194-206.e17. doi: 10.1016/j.exphem.2015.11.003. Epub 2015 Nov 19.

15.

c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.

Muvarak N, Kelley S, Robert C, Baer MR, Perrotti D, Gambacorti-Passerini C, Civin C, Scheibner K, Rassool FV.

Mol Cancer Res. 2015 Apr;13(4):699-712. doi: 10.1158/1541-7786.MCR-14-0422. Epub 2015 Mar 31.

16.

Regulation of RAB5C is important for the growth inhibitory effects of MiR-509 in human precursor-B acute lymphoblastic leukemia.

Tan YS, Kim M, Kingsbury TJ, Civin CI, Cheng WC.

PLoS One. 2014 Nov 4;9(11):e111777. doi: 10.1371/journal.pone.0111777. eCollection 2014.

17.

Identification of miR-145 targets through an integrated omics analysis.

Huang TC, Renuse S, Pinto S, Kumar P, Yang Y, Chaerkady R, Godsey B, Mendell JT, Halushka MK, Civin CI, Marchionni L, Pandey A.

Mol Biosyst. 2015 Jan;11(1):197-207. doi: 10.1039/c4mb00585f. Epub 2014 Oct 30.

18.

MIR144 and MIR451 regulate human erythropoiesis via RAB14.

Kim M, Tan YS, Cheng WC, Kingsbury TJ, Heimfeld S, Civin CI.

Br J Haematol. 2015 Feb;168(4):583-97. doi: 10.1111/bjh.13164. Epub 2014 Oct 14.

19.

Integrated analysis of CRLF2 signaling in acute lymphoblastic leukemia identifies Polo-like kinase 1 as a potential therapeutic target.

Huang TC, Cutler J, Bharne S, Zhong J, Weinstock D, Tyner J, Gojo I, Civin C, Pandey A.

Leuk Lymphoma. 2015 May;56(5):1524-7. doi: 10.3109/10428194.2014.963076. Epub 2014 Nov 5. No abstract available.

20.

Correlated miR-mRNA expression signatures of mouse hematopoietic stem and progenitor cell subsets predict "Stemness" and "Myeloid" interaction networks.

Heiser D, Tan YS, Kaplan I, Godsey B, Morisot S, Cheng WC, Small D, Civin CI.

PLoS One. 2014 Apr 18;9(4):e94852. doi: 10.1371/journal.pone.0094852. eCollection 2014.

21.

Hepcidin-dependent and hepcidin-independent regulation of erythropoiesis in a mouse model of anemia of chronic inflammation.

Langdon JM, Yates SC, Femnou LK, McCranor BJ, Cheadle C, Xue QL, Vaulont S, Civin CI, Walston JD, Roy CN.

Am J Hematol. 2014 May;89(5):470-9. doi: 10.1002/ajh.23670. Epub 2014 Feb 24.

22.

Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells.

McCranor BJ, Kim MJ, Cruz NM, Xue QL, Berger AE, Walston JD, Civin CI, Roy CN.

Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):126-33. doi: 10.1016/j.bcmd.2013.09.004. Epub 2013 Oct 9. Erratum in: Blood Cells Mol Dis. 2014 Apr;52(4):236.

23.

Investigation of the role of interleukin-6 and hepcidin antimicrobial peptide in the development of anemia with age.

McCranor BJ, Langdon JM, Prince OD, Femnou LK, Berger AE, Cheadle C, Civin CI, Kim A, Rivera S, Ganz T, Vaulont S, Xue QL, Walston JD, Roy CN.

Haematologica. 2013 Oct;98(10):1633-40. doi: 10.3324/haematol.2013.087114. Epub 2013 Aug 30.

24.

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.

Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T.

Blood. 2013 Aug 15;122(7):1293-304. doi: 10.1182/blood-2013-05-501072. Epub 2013 Jul 8.

25.

Artemisinin-derived dimer phosphate esters as potent anti-cytomegalovirus (anti-CMV) and anti-cancer agents: a structure-activity study.

Mott BT, He R, Chen X, Fox JM, Civin CI, Arav-Boger R, Posner GH.

Bioorg Med Chem. 2013 Jul 1;21(13):3702-7. doi: 10.1016/j.bmc.2013.04.027. Epub 2013 Apr 22.

26.

A simple high-throughput technology enables gain-of-function screening of human microRNAs.

Cheng WC, Kingsbury TJ, Wheelan SJ, Civin CI.

Biotechniques. 2013 Feb;54(2):77-86. doi: 10.2144/000113991.

27.

Biochemistry and signaling in stem cells, and vice versa.

Farrance I, Civin C.

Biochim Biophys Acta. 2013 Feb;1830(2):2267. doi: 10.1016/j.bbagen.2012.12.002. No abstract available.

PMID:
23331875
28.

Inferring microRNA regulation of mRNA with partially ordered samples of paired expression data and exogenous prediction algorithms.

Godsey B, Heiser D, Civin C.

PLoS One. 2012;7(12):e51480. doi: 10.1371/journal.pone.0051480. Epub 2012 Dec 19.

29.

MiR-27a functions as a tumor suppressor in acute leukemia by regulating 14-3-3θ.

Scheibner KA, Teaboldt B, Hauer MC, Chen X, Cherukuri S, Guo Y, Kelley SM, Liu Z, Baer MR, Heimfeld S, Civin CI.

PLoS One. 2012;7(12):e50895. doi: 10.1371/journal.pone.0050895. Epub 2012 Dec 7.

30.

FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.

Chu SH, Heiser D, Li L, Kaplan I, Collector M, Huso D, Sharkis SJ, Civin C, Small D.

Cell Stem Cell. 2012 Sep 7;11(3):346-58. doi: 10.1016/j.stem.2012.05.027.

31.

Generation and genetic engineering of human induced pluripotent stem cells using designed zinc finger nucleases.

Ramalingam S, London V, Kandavelou K, Cebotaru L, Guggino W, Civin C, Chandrasegaran S.

Stem Cells Dev. 2013 Feb 15;22(4):595-610. doi: 10.1089/scd.2012.0245. Epub 2012 Oct 19.

32.

Late stage erythroid precursor production is impaired in mice with chronic inflammation.

Prince OD, Langdon JM, Layman AJ, Prince IC, Sabogal M, Mak HH, Berger AE, Cheadle C, Chrest FJ, Yu Q, Andrews NC, Xue QL, Civin CI, Walston JD, Roy CN.

Haematologica. 2012 Nov;97(11):1648-56. doi: 10.3324/haematol.2011.053397. Epub 2012 May 11.

33.

Pluripotent stem cell-based cancer therapy: promise and challenges.

Sharkis SJ, Jones RJ, Civin C, Jang YY.

Sci Transl Med. 2012 Mar 28;4(127):127ps9. doi: 10.1126/scitranslmed.3003920. Review.

34.

Mice deficient in MIM expression are predisposed to lymphomagenesis.

Yu D, Zhan XH, Zhao XF, Williams MS, Carey GB, Smith E, Scott D, Zhu J, Guo Y, Cherukuri S, Civin CI, Zhan X.

Oncogene. 2012 Jul 26;31(30):3561-8. doi: 10.1038/onc.2011.509. Epub 2011 Nov 14.

35.

Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.

Zhang H, Cui Y, Voong N, Sabatino M, Stroncek DF, Morisot S, Civin CI, Wayne AS, Levine BL, Mackall CL.

J Immunother. 2011 Mar;34(2):187-95. doi: 10.1097/CJI.0b013e31820d2a21.

36.

Deletion of tristetraprolin caused spontaneous reactive granulopoiesis by a non-cell-autonomous mechanism without disturbing long-term hematopoietic stem cell quiescence.

Kaplan IM, Morisot S, Heiser D, Cheng WC, Kim MJ, Civin CI.

J Immunol. 2011 Mar 1;186(5):2826-34. doi: 10.4049/jimmunol.1002806. Epub 2011 Jan 26.

37.

Cutting edge: The transcription factor Kruppel-like factor 4 regulates the differentiation of Th17 cells independently of RORγt.

Lebson L, Gocke A, Rosenzweig J, Alder J, Civin C, Calabresi PA, Whartenby KA.

J Immunol. 2010 Dec 15;185(12):7161-4. doi: 10.4049/jimmunol.1002750. Epub 2010 Nov 12.

38.

High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias.

Morisot S, Wayne AS, Bohana-Kashtan O, Kaplan IM, Gocke CD, Hildreth R, Stetler-Stevenson M, Walker RL, Davis S, Meltzer PS, Wheelan SJ, Brown P, Jones RJ, Shultz LD, Civin CI.

Leukemia. 2010 Nov;24(11):1859-66. doi: 10.1038/leu.2010.184. Epub 2010 Aug 26.

39.

Mobile interspersed repeats are major structural variants in the human genome.

Huang CR, Schneider AM, Lu Y, Niranjan T, Shen P, Robinson MA, Steranka JP, Valle D, Civin CI, Wang T, Wheelan SJ, Ji H, Boeke JD, Burns KH.

Cell. 2010 Jun 25;141(7):1171-82. doi: 10.1016/j.cell.2010.05.026.

40.

CD34 stem cell stories and lessons from the CD34 wars: the Landsteiner Lecture 2009.

Civin CI.

Transfusion. 2010 Sep;50(9):2046-56. doi: 10.1111/j.1537-2995.2010.02729.x. Review. No abstract available.

PMID:
20561292
41.

Targeted manipulation of mammalian genomes using designed zinc finger nucleases.

Kandavelou K, Ramalingam S, London V, Mani M, Wu J, Alexeev V, Civin CI, Chandrasegaran S.

Biochem Biophys Res Commun. 2009 Oct 9;388(1):56-61. doi: 10.1016/j.bbrc.2009.07.112. Epub 2009 Jul 25.

42.

Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand.

Bohana-Kashtan O, Morisot S, Hildreth R, Brayton C, Levitsky HI, Civin CI.

J Immunol. 2009 Jul 1;183(1):696-705. doi: 10.4049/jimmunol.0800561. Epub 2009 Jun 17.

43.

Notch signaling activation in human embryonic stem cells is required for embryonic, but not trophoblastic, lineage commitment.

Yu X, Zou J, Ye Z, Hammond H, Chen G, Tokunaga A, Mali P, Li YM, Civin C, Gaiano N, Cheng L.

Cell Stem Cell. 2008 May 8;2(5):461-71. doi: 10.1016/j.stem.2008.03.001.

44.

Kruppel-like factor 4 is essential for inflammatory monocyte differentiation in vivo.

Alder JK, Georgantas RW 3rd, Hildreth RL, Kaplan IM, Morisot S, Yu X, McDevitt M, Civin CI.

J Immunol. 2008 Apr 15;180(8):5645-52.

45.

CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control.

Georgantas RW 3rd, Hildreth R, Morisot S, Alder J, Liu CG, Heimfeld S, Calin GA, Croce CM, Civin CI.

Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2750-5. Epub 2007 Feb 9.

46.

Ex vivo expansion of mafosfamide-purged PBPC products.

McNiece I, Civin C, Harrington J, Kellner J, Malehorn M, Turney J, Barber J, Jones R.

Cytotherapy. 2006;8(5):459-64.

PMID:
17050250
47.

Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.

Georgantas RW 3rd, Bohana-Kashtan O, Civin CI.

Transplantation. 2006 Aug 27;82(4):471-8.

PMID:
16926590
48.

Identification of a region on the outer surface of the CBFbeta-SMMHC myeloid oncoprotein assembly competence domain critical for multimerization.

Zhang L, D'Costa J, Kummalue T, Civin CI, Friedman AD.

Oncogene. 2006 Nov 23;25(55):7289-96. Epub 2006 Jun 12.

PMID:
16767164
49.

Troublesome questions.

Civin CI.

Stem Cells. 2006 Jun;24(6):1411. Epub 2006 May 10. No abstract available.

50.

C/EBPalpha directs monocytic commitment of primary myeloid progenitors.

Wang D, D'Costa J, Civin CI, Friedman AD.

Blood. 2006 Aug 15;108(4):1223-9. Epub 2006 Apr 27.

Supplemental Content

Support Center